EZH2 and cancer: Global deletion of Ezh2 in mature naïve T cells as in the Ezh2fl/flCd4Cre T cells obscures the possible benefits of EZH2 inhibition, where potency of EZH2 inhibitors as well as pharmacological inhibitor treatment of the whole organism can alter the functional outcomes as observed in cancer models (33, 48).